ABS-201
AI-designed antibody targeting prolactin receptor for androgenetic alopecia treatment
Device · OtherCompany source
Company profile
About Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Company description Absci official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Absci?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Androgenetic Alopecia (AGA)
- challenging therapeutic targets across multiple disease areas
- oncology
Who it serves
- Academic institutions
- Biotech
- Pharma
- Technology companies
Deployment & integration
On Premise · Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Phase 1/2a clinical trial for ABS-201 initiated December 2025; Origin-1 de novo antibody design platform released; developed ABS-201 from concept to clinical trial in 24 months; amassing exponentially larger data moat since 2020
Partnerships
Recorded partners
- Almirall
- AMD
- AstraZeneca
- Invetx
- Merck Global Health Innovation Fund
- NVIDIA
- Owkin
- PrecisionLife
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ACE Assay
High-throughput antibody screening technology with 4,000x traditional throughput
Platform · On PremiseCompany source
AI Target Discovery (Reverse Immunology)
AI-enabled novel target discovery using reverse immunology approach
Platform · On PremiseCompany source
Integrated Drug Creation Platform
AI-powered platform for de novo biologics design and optimization
Platform · On PremiseCompany source
Origin-1
Generative AI platform for de novo antibody design against zero-prior epitopes
Platform · On PremiseCompany source
SoluPro
Synthetic biology technology for high-throughput protein expression
Platform · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.mAbs · Dec 1, 2026
Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis.Nature microbiology · Nov 1, 2024
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.Nature medicine · Oct 1, 2024
Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates.Science (New York, N.Y.) · Aug 9, 2024
Identifying transgene insertions in Caenorhabditis elegans genomes with Oxford Nanopore sequencing.PeerJ · Jan 1, 2024
Genome Size Changes by Duplication, Divergence, and Insertion in Caenorhabditis Worms.Molecular biology and evolution · Mar 4, 2023
Clinical validation
Clinical-trial records
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic AlopeciaNCT07317544 · Sponsor · RECRUITING
To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord InjuryNCT01730183 · Mentioned · UNKNOWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Target to promising leads in 14 months
Integrated Drug Creation platform timeline from target identification to development candidates
Potential Best-in-Class therapeutic in 24 months
ABS-201 development from concept through to clinical trial pipeline
6 week cycle times
Data to train, AI to create, wet lab to validate iterative cycles
>4,000x throughput
ACE Assay vs traditional antibody screening assays
Absci Internal Pipeline - ABS-201
Developed a potential Best-in-Class therapeutic antibody for androgenetic alopecia targeting prolactin receptors
24 months from concept to clinical trial pipeline; Phase 1/2a initiated December 2025
Almirall
Using Absci's de novo platform to address industry's most challenging targets with high unmet medical need
Partnership for novel innovation on challenging drug targets
AMD
Technology partnership to accelerate breakthroughs in therapeutics and transform how biologic drugs are developed
Partnership to power AI-driven drug discovery infrastructure
AstraZeneca
Utilizing Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology
Collaboration to design novel antibody therapy in oncology using AI platform
Invetx
Building scalable platform for bringing innovative specialty therapeutics for companion animals to market using generative AI design of human antibodies
Partnership for veterinary therapeutics development
Merck Global Health Innovation Fund
Investment in Next Horizon technologies with potential to disrupt the biopharmaceutical industry and impact human health
Strategic investment partnership for AI-driven drug discovery
NVIDIA
Powering and scaling Absci's in silico technologies for drug discovery
Technology partnership to scale AI protein engineering platform
Owkin
Combining Owkin's AI agents for target identification with Absci's biologic drug candidate development capabilities
Partnership to accelerate delivery of next-generation treatments
PrecisionLife
Coupling leading generative AI approaches with PrecisionLife's unique disease biology insights for transformational innovation
Partnership combining AI and disease biology insights
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Puja Spara
Senior Vice President of Biologics Engineering & Oncology Targeted Delivery, AstraZeneca
Prem Tumkosit
Managing Director, Merck Global Health Innovation Fund
Mark Papermaster
Executive Vice President and Chief Technology Officer, AMD
Steve Gardner
CEO & Co-founder, PrecisionLife
Karl Ziegelbauer
Executive Vice President of R&D and Chief Scientific Officer, Almirall
Kimberly Powell
Vice President of Healthcare, NVIDIA
Thomas Clozel
CEO and Co-Founder, Owkin
Juergen Horn
President, Invetx
06 · Company updates
Updates from Absci
Recent articles published on Absci's official website.
Development of ABS-101: A potential best-in-class anti-TL1A antibody for the treatment of IBD
Read on AbsciThe Pre-clinical Science Behind ABS-201 for Endometriosis
Read on AbsciProlactin Receptor Blockade With ABS-201 Relieves Pain and Inflammation in a Homologous Transplant Mouse Model of Endometriosis
Read on AbsciABS-201 Case Study: Potential best-in-class antibody targeting the prolactin receptor for the treatment of androgenic alopecia
Read on AbsciProlactin Receptor Blockade With ABS-201 Relieves Pain and Inflammation in a Homologous Transplant Mouse Model of Endometriosis
Read on Absci07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.